{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T01:46:16Z","timestamp":1788486376593,"version":"build-2803163510"},"reference-count":60,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T00:00:00Z","timestamp":1649116800000},"content-version":"vor","delay-in-days":28,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Breast Cancer Research Institute"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,3,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Axillary lymph node status remains the most powerful prognostic indicator in invasive breast cancer. Ductal carcinoma in situ (DCIS) is a non-invasive disease and does not spread to axillary lymph nodes. The presence of an invasive component to DCIS mandates nodal evaluation through sentinel lymph node biopsy (SLNB). Quantification of the necessity of upfront SLNB for DCIS requires investigation. The aim was to establish the likelihood of having a positive SLNB (SLNB+) for DCIS and to establish parameters predictive of SLNB+.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A systematic review was performed as per the PRISMA guidelines. Prospective studies only were included. Characteristics predictive of SLNB+ were expressed as dichotomous variables and pooled as odds ratios (o.r.) and associated 95 per cent confidence intervals (c.i.) using the Mantel\u2013Haenszel method.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Overall, 16 studies including 4388 patients were included (mean patient age 54.8 (range 24 to 92) years). Of these, 72.5 per cent of patients underwent SLNB (3156 of 4356 patients) and 4.9 per cent had SLNB+ (153 of 3153 patients). The likelihood of having SLNB+ for DCIS was less than 1 per cent (o.r. &amp;lt;0.01, 95 per cent c.i. 0.00 to 0.01; P\u2009&amp;lt;\u20090.001, I2\u2009=\u200993 per cent). Palpable DCIS (o.r. 2.01, 95 per cent c.i. 0.64 to 6.24; P\u2009=\u20090.230, I2\u2009=\u20090 per cent), tumour necrosis (o.r. 3.84, 95 per cent c.i. 0.85 to 17.44; P\u2009=\u20090.080, I2\u2009=\u200983 per cent), and grade 3 DCIS (o.r. 1.34, 95 per cent c.i. 0.80 to 2.23; P\u2009=\u20090.270, I2\u2009=\u20090 per cent) all trended towards significance in predicting SLNB+.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>While aggressive clinicopathological parameters may guide SLNB for patients with DCIS, the absolute and relative risk of SLNB+ for DCIS is less than 5 per cent and 1 per cent, respectively. Well-designed randomized controlled trials are required to establish fully the necessity of SLNB for patients diagnosed with DCIS.<\/jats:p><\/jats:sec><jats:sec><jats:title>Registration number<\/jats:title><jats:p>CRD42021284194 (https:\/\/www.crd.york.ac.uk\/prospero\/)<\/jats:p><\/jats:sec>","DOI":"10.1093\/bjsopen\/zrac022","type":"journal-article","created":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T20:10:27Z","timestamp":1643832627000},"source":"Crossref","is-referenced-by-count":23,"title":["Sentinel lymph node biopsy in patients with ductal carcinoma<i>in situ<\/i>: systematic review and meta-analysis"],"prefix":"10.1093","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9892-9920","authenticated-orcid":false,"given":"Matthew G.","family":"Davey","sequence":"first","affiliation":[{"name":"Department of Surgery, The Lambe Institute for Translational Research, National University of Ireland, Galway, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colm","family":"O\u2019Flaherty","sequence":"additional","affiliation":[{"name":"Department of Surgery, The Lambe Institute for Translational Research, National University of Ireland, Galway, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2750-3057","authenticated-orcid":false,"given":"Eoin F.","family":"Cleere","sequence":"additional","affiliation":[{"name":"Department of Surgery, The Lambe Institute for Translational Research, National University of Ireland, Galway, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aoife","family":"Nohilly","sequence":"additional","affiliation":[{"name":"Department of Surgery, The Lambe Institute for Translational Research, National University of Ireland, Galway, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Phelan","sequence":"additional","affiliation":[{"name":"Department of Surgery, The Lambe Institute for Translational Research, National University of Ireland, Galway, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan","family":"Ronane","sequence":"additional","affiliation":[{"name":"Department of Surgery, The Lambe Institute for Translational Research, National University of Ireland, Galway, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aoife J.","family":"Lowery","sequence":"additional","affiliation":[{"name":"Department of Surgery, The Lambe Institute for Translational Research, National University of Ireland, Galway, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4164-5561","authenticated-orcid":false,"given":"Michael J.","family":"Kerin","sequence":"additional","affiliation":[{"name":"Department of Surgery, The Lambe Institute for Translational Research, National University of Ireland, Galway, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,4,5]]},"reference":[{"key":"2022040513343388800_zrac022-B1","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1093\/jncimonographs\/lgq024","article-title":"Ductal carcinoma in situ: risk factors and impact of screening","volume":"2010","author":"Virnig","year":"2010","journal-title":"J Natl Cancer Inst Monogr"},{"key":"2022040513343388800_zrac022-B2","doi-asserted-by":"crossref","first-page":"912","DOI":"10.2214\/AJR.20.23314","article-title":"Digital mammography has persistently increased high-grade and overall DCIS detection without altering upgrade rate","volume":"216","author":"Neal","year":"2021","journal-title":"AJR Am J Roentgenol"},{"key":"2022040513343388800_zrac022-B3","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21442","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"2022040513343388800_zrac022-B4","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s12262-013-0987-0","article-title":"Ductal carcinoma in situ of the breast","volume":"77","author":"Vaidya","year":"2015","journal-title":"Indian J Surg"},{"key":"2022040513343388800_zrac022-B5","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s12893-021-01170-x","article-title":"Necessity of sentinel lymph node biopsy in ductal carcinoma in situ patients: a retrospective analysis","volume":"21","author":"Shin","year":"2021","journal-title":"BMC Surg"},{"key":"2022040513343388800_zrac022-B6","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s10549-018-4820-0","article-title":"Long-term breast cancer survival in relation to the metastatic tumor burden in axillary lymph nodes","volume":"171","author":"Andersson","year":"2018","journal-title":"Breast Cancer Res Treat"},{"key":"2022040513343388800_zrac022-B7","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1200\/JCO.2000.18.13.2553","article-title":"Prospective observational study of sentinel lymphadenectomy without further axillary dissection in patients with sentinel node\u2013negative breast cancer","volume":"18","author":"Giuliano","year":"2000","journal-title":"J Clin Oncol"},{"key":"2022040513343388800_zrac022-B8","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1056\/NEJMoa012782","article-title":"A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer","volume":"349","author":"Veronesi","year":"2003","journal-title":"N Engl J Med"},{"key":"2022040513343388800_zrac022-B9","first-page":"11782234211022203","article-title":"Evaluating the clinical utility of routine sentinel lymph node biopsy and the value of adjuvant chemotherapy in elderly patients diagnosed with oestrogen receptor positive, clinically node negative breast cancer","volume":"15","author":"Davey","year":"2021","journal-title":"Breast Cancer (Auckl)"},{"key":"2022040513343388800_zrac022-B10","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1001\/jama.2011.90","article-title":"Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial","volume":"305","author":"Giuliano","year":"2011","journal-title":"JAMA"},{"key":"2022040513343388800_zrac022-B11","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1200\/JCO.2013.54.1177","article-title":"Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update","volume":"32","author":"Lyman","year":"2014","journal-title":"J Clin Oncol"},{"key":"2022040513343388800_zrac022-B12","article-title":"Early and locally advanced breast cancer: diagnosis and management","author":"NICE"},{"key":"2022040513343388800_zrac022-B13","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.ejso.2013.10.020","article-title":"Sentinel lymph node biopsy in patients with microinvasive breast cancer: a systematic review and meta-analysis","volume":"40","author":"Gojon","year":"2014","journal-title":"Eur J Surg Oncol"},{"key":"2022040513343388800_zrac022-B14","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"2022040513343388800_zrac022-B15","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group","volume":"283","author":"Stroup","year":"2000","journal-title":"JAMA"},{"key":"2022040513343388800_zrac022-B16","first-page":"25","article-title":"The well-built clinical question: the key to finding the best evidence efficiently","volume":"98","author":"Armstrong","year":"1999","journal-title":"WMJ"},{"key":"2022040513343388800_zrac022-B17","doi-asserted-by":"crossref","first-page":"290","DOI":"10.3322\/caac.21393","article-title":"Breast cancer\u2014major changes in the American Joint Committee on Cancer eighth edition cancer staging manual","volume":"67","author":"Giuliano","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"2022040513343388800_zrac022-B18","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"2022040513343388800_zrac022-B19","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"2022040513343388800_zrac022-B20","doi-asserted-by":"crossref","first-page":"152","DOI":"10.5395\/rde.2017.42.2.152","article-title":"Statistical notes for clinical researchers: chi-squared test and Fisher\u2019s exact test","volume":"42","author":"Kim","year":"2017","journal-title":"Restor Dent Endod"},{"key":"2022040513343388800_zrac022-B21","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/S0002-9610(03)00276-9","article-title":"Axillary lymph node metastases in patients with a final diagnosis of ductal carcinoma in situ","volume":"186","author":"Kelly","year":"2003","journal-title":"Am J Surg"},{"key":"2022040513343388800_zrac022-B22","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.cursur.2004.09.011","article-title":"Core biopsy diagnosis of ductal carcinoma in situ: an indication for sentinel lymph node biopsy","volume":"62","author":"Mittendorf","year":"2005","journal-title":"Curr Surg"},{"key":"2022040513343388800_zrac022-B23","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.breast.2013.12.002","article-title":"Extensive pure ductal carcinoma in situ of the breast: identification of predictors of associated infiltrating carcinoma and lymph node metastasis before immediate reconstructive surgery","volume":"23","author":"Guillot","year":"2014","journal-title":"Breast"},{"key":"2022040513343388800_zrac022-B24","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s10549-006-9167-2","article-title":"Is there a role of sentinel lymph node biopsy in ductal carcinoma in situ?: analysis of 587 cases","volume":"98","author":"Goyal","year":"2006","journal-title":"Breast Cancer Res Treat"},{"key":"2022040513343388800_zrac022-B25","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.amjsurg.2006.11.027","article-title":"Role of sentinel lymph node biopsy in high-risk ductal carcinoma in situ patients","volume":"194","author":"Moran","year":"2007","journal-title":"Am J Surg"},{"key":"2022040513343388800_zrac022-B26","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1097\/MNM.0b013e328349eafc","article-title":"Selective approach to radionuclide-guided sentinel lymph node biopsy in high-risk ductal carcinoma in situ of the breast","volume":"32","author":"Usmani","year":"2011","journal-title":"Nucl Med Commun"},{"key":"2022040513343388800_zrac022-B27","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1177\/030089160909500612","article-title":"Sentinel lymph node biopsy in patients with pure and high-risk ductal carcinoma in situ of the breast","volume":"95","author":"D\u2019Eredit\u00e0","year":"2009","journal-title":"Tumori J"},{"key":"2022040513343388800_zrac022-B28","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s12094-010-0543-3","article-title":"Sentinel lymph node biopsy in selected cases of ductal carcinoma in situ","volume":"12","author":"Collado","year":"2010","journal-title":"Clin Transl Oncol"},{"key":"2022040513343388800_zrac022-B29","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1007\/s10434-000-0636-2","article-title":"Sentinel lymph node biopsy: is it indicated in patients with high-risk ductal carcinoma-in-situ and ductal carcinoma-in-situ with microinvasion?","volume":"7","author":"Klauber-DeMore","year":"2000","journal-title":"Ann Surg Oncol"},{"key":"2022040513343388800_zrac022-B30","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1177\/030089161209800403","article-title":"Sentinel node biopsy in early breast cancer: lessons learned from more than 1000 cases at a single institution","volume":"98","author":"Fancellu","year":"2012","journal-title":"Tumori J"},{"key":"2022040513343388800_zrac022-B31","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1001\/archsurg.138.3.309","article-title":"Axillary sentinel lymph node biopsy in patients with pure ductal carcinoma in situ of the breast","volume":"138","author":"Intra","year":"2003","journal-title":"Arch Surg"},{"key":"2022040513343388800_zrac022-B32","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1245\/s10434-015-4476-5","article-title":"The role of sentinel lymph node biopsy and factors associated with invasion in extensive DCIS of the breast treated by mastectomy: the Cinnamome prospective multicenter study","volume":"22","author":"Tunon-de-Lara","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"2022040513343388800_zrac022-B33","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.ejso.2007.08.003","article-title":"The value of sentinel lymph node biopsy in ductal carcinoma in situ (DCIS) and DCIS with microinvasion of the breast","volume":"34","author":"van la Parra","year":"2008","journal-title":"Eur J Surg Oncol"},{"key":"2022040513343388800_zrac022-B34","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1002\/jso.20581","article-title":"Tumour-positive sentinel node findings in patients with ductal carcinoma in situ","volume":"94","author":"Leidenius","year":"2006","journal-title":"J Surg Oncol"},{"key":"2022040513343388800_zrac022-B35","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1002\/jso.23273","article-title":"Risk predictors of underestimation and the need for sentinel node biopsy in patients diagnosed with ductal carcinoma in situ by preoperative needle biopsy","volume":"107","author":"Park","year":"2013","journal-title":"J Surg Oncol"},{"key":"2022040513343388800_zrac022-B36","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/bjs.9404","article-title":"Incidence of and risk factors for sentinel lymph node metastasis in patients with a postoperative diagnosis of ductal carcinoma in situ","volume":"101","author":"Zetterlund","year":"2014","journal-title":"Br J Surg"},{"key":"2022040513343388800_zrac022-B37","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.amjsurg.2016.04.019","article-title":"Is sentinel lymph node biopsy indicated in patients with a diagnosis of ductal carcinoma in situ? A systematic literature review and meta-analysis","volume":"213","author":"El Hage Chehade","year":"2017","journal-title":"Am J Surg"},{"key":"2022040513343388800_zrac022-B38","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.amjsurg.2018.06.013","article-title":"Ductal carcinoma in situ current trends, controversies, and review of literature","volume":"216","author":"Hong","year":"2018","journal-title":"Am J Surg"},{"key":"2022040513343388800_zrac022-B39","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1016\/j.acra.2020.02.011","article-title":"Noncalcified ductal carcinoma in situ (DCIS): rate and predictors of upgrade to invasive carcinoma","volume":"28","author":"Lamb","year":"2021","journal-title":"Acad Radiol"},{"key":"2022040513343388800_zrac022-B40","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/s41416-019-0478-6","article-title":"Ductal carcinoma in situ: to treat or not to treat, that is the question","volume":"121","author":"van Seijen","year":"2019","journal-title":"Br J Cancer"},{"key":"2022040513343388800_zrac022-B41","doi-asserted-by":"crossref","first-page":"GS3","DOI":"10.1158\/1538-7445.SABCS20-GS3-00","article-title":"Abstract GS3-00: first results from a phase III randomized clinical trial of standard adjuvant endocrine therapy (ET) +\/- chemotherapy (CT) in patients (pts) with 1\u20133 positive nodes, hormone receptor-positive (HR+) and HER2-negative (HER2-) breast cancer (BC) with recurrence score (RS) &lt;25: SWOG S1007 (RxPonder)","volume":"81","author":"Kalinsky","year":"2021","journal-title":"Cancer Res"},{"key":"2022040513343388800_zrac022-B42","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1159\/000516114","article-title":"St. Gallen\/Vienna 2021: a brief summary of the consensus discussion on customizing therapies for women with early breast cancer","volume":"16","author":"Thomssen","year":"2021","journal-title":"Breast Care"},{"key":"2022040513343388800_zrac022-B43","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.clbc.2013.08.002","article-title":"Palpable ductal carcinoma in situ: analysis of radiological and histological features of a large series with 5-year follow-up","volume":"13","author":"Sundara Rajan","year":"2013","journal-title":"Clin Breast Cancer"},{"key":"2022040513343388800_zrac022-B44","first-page":"123549","article-title":"Ductal carcinoma in situ of the breast","volume":"2012","author":"Lee","year":"2012","journal-title":"Int J Surg Oncol"},{"key":"2022040513343388800_zrac022-B45","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1093\/jnci\/djg097","article-title":"Characteristics associated with recurrence among women with ductal carcinoma in situ treated by lumpectomy","volume":"95","author":"Kerlikowske","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"2022040513343388800_zrac022-B46","doi-asserted-by":"crossref","first-page":"609","DOI":"10.3390\/cancers12030609","article-title":"Ductal carcinoma in situ of the breast: an update with emphasis on radiological and morphological features as predictive prognostic factors","volume":"12","author":"Salvatorelli","year":"2020","journal-title":"Cancers"},{"key":"2022040513343388800_zrac022-B47","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/s41416-020-01152-5","article-title":"Pathological features of 11,337 patients with primary ductal carcinoma in situ (DCIS) and subsequent events: results from the UK Sloane Project","volume":"124","author":"Shaaban","year":"2021","journal-title":"Br J Cancer"},{"key":"2022040513343388800_zrac022-B48","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1038\/s41388-018-0555-y","article-title":"Tissue necrosis and its role in cancer progression","volume":"38","author":"Karsch-Bluman","year":"2019","journal-title":"Oncogene"},{"key":"2022040513343388800_zrac022-B49","doi-asserted-by":"crossref","first-page":"3537471","DOI":"10.1155\/2018\/3537471","article-title":"Regulation of tumor progression by programmed necrosis","volume":"2018","author":"Lee","year":"2018","journal-title":"Oxid Med Cell Longev"},{"key":"2022040513343388800_zrac022-B50","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/s41379-019-0204-1","article-title":"Ductal carcinoma in situ of the breast: an update for the pathologist in the era of individualized risk assessment and tailored therapies","volume":"32","author":"Hanna","year":"2019","journal-title":"Mod Pathol"},{"key":"2022040513343388800_zrac022-B51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4132\/jptm.2020.11.20","article-title":"Standardized pathology report for breast cancer","volume":"55","author":"Cho","year":"2021","journal-title":"J Pathol Transl Med"},{"key":"2022040513343388800_zrac022-B52","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.breast.2021.02.001","article-title":"Combined breast conservation therapy versus mastectomy for BRCA mutation carriers\u2014a systematic review and meta-analysis","volume":"56","author":"Davey","year":"2021","journal-title":"Breast"},{"key":"2022040513343388800_zrac022-B53","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1804710","article-title":"Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer","volume":"379","author":"Sparano","year":"2018","journal-title":"N Engl J Med"},{"key":"2022040513343388800_zrac022-B54","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/tbj.14217","article-title":"Clinicopathological correlates, oncological impact, and validation of Oncotype DX\u2122 in a European Tertiary Referral Centre","volume":"27","author":"Davey","year":"2021","journal-title":"Breast J"},{"key":"2022040513343388800_zrac022-B55","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1056\/NEJMoa1602253","article-title":"70-gene signature as an aid to treatment decisions in early-stage breast cancer","volume":"375","author":"Cardoso","year":"2016","journal-title":"N Engl J Med"},{"key":"2022040513343388800_zrac022-B56","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1093\/annonc\/mdt303","article-title":"Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013","volume":"24","author":"Goldhirsch","year":"2013","journal-title":"Ann Oncol"},{"key":"2022040513343388800_zrac022-B57","doi-asserted-by":"crossref","first-page":"10812","DOI":"10.3390\/ijms221910812","article-title":"MicroRNA expression profiles and breast cancer chemotherapy","volume":"22","author":"Davey","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2022040513343388800_zrac022-B58","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s10549-015-3464-6","article-title":"A population-based validation study of the DCIS Score predicting recurrence risk in individuals treated by breast-conserving surgery alone","volume":"152","author":"Rakovitch","year":"2015","journal-title":"Breast Cancer Res Treat"},{"key":"2022040513343388800_zrac022-B59","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1093\/jnci\/djt067","article-title":"A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast","volume":"105","author":"Solin","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"2022040513343388800_zrac022-B60","article-title":"Sentinel lymph node biopsy in ductal cancer in situ or unclear lesions of the breast and how to not do it","author":"Karakatsanis"}],"container-title":["BJS Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjsopen\/article-pdf\/6\/2\/zrac022\/43258302\/zrac022.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjsopen\/article-pdf\/6\/2\/zrac022\/43258302\/zrac022.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T17:33:17Z","timestamp":1674667997000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjsopen\/article\/doi\/10.1093\/bjsopen\/zrac022\/6563503"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,8]]},"references-count":60,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,3,8]]}},"URL":"https:\/\/doi.org\/10.1093\/bjsopen\/zrac022","relation":{},"ISSN":["2474-9842"],"issn-type":[{"value":"2474-9842","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,4,1]]},"published":{"date-parts":[[2022,3,8]]},"article-number":"zrac022"}}